DBVE-PC regimen: Difference between revisions
No edit summary |
|||
| Line 9: | Line 9: | ||
==Regimen== | ==Regimen== | ||
[[ | [[Doxorubicin|{{button|D – Doxorubicin}}]] | ||
[[ | [[Bleomycin|{{button|B – Bleomycin}}]] | ||
[[ | [[Vincristine|{{button|V – Vincristine}}]] | ||
[[ | [[Etoposide|{{button|E – Etoposide}}]] | ||
[[Prednisone|{{button|P – Prednisone}}]] | [[Prednisone|{{button|P – Prednisone}}]] | ||
[[Cyclophosphamide|{{button|C – Cyclophosphamide}}]] | |||
==Indications== | ==Indications== | ||
Revision as of 14:21, 27 February 2015
|
WikiDoc Resources for DBVE-PC regimen |
|
Articles |
|---|
|
Most recent articles on DBVE-PC regimen Most cited articles on DBVE-PC regimen |
|
Media |
|
Powerpoint slides on DBVE-PC regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on DBVE-PC regimen at Clinical Trials.gov Trial results on DBVE-PC regimen Clinical Trials on DBVE-PC regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on DBVE-PC regimen NICE Guidance on DBVE-PC regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on DBVE-PC regimen Discussion groups on DBVE-PC regimen Patient Handouts on DBVE-PC regimen Directions to Hospitals Treating DBVE-PC regimen Risk calculators and risk factors for DBVE-PC regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for DBVE-PC regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: ABVE-PC Regimen; Adriamycin-Bleomycin-Vincristine-Etoposide/Prednisone-Cyclophosphamide Regimen; DBVE-PC; POG 9245 Regimen
Overview
DBVE-PC regimen refers to a regimen consisting of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide, given in combination with radiation therapy and used for the treatment of high-risk, childhood Hodgkin's lymphoma.[1][2]
Regimen
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Coiffier, Bertrand (2002-01-24). "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma". The New England Journal of Medicine. 346 (4): 235–242. doi:10.1056/NEJMoa011795. ISSN 1533-4406. PMID 11807147. Unknown parameter
|coauthors=ignored (help) - ↑ Kluin-Nelemans, H. C. (2012-08-09). "Treatment of older patients with mantle-cell lymphoma". The New England Journal of Medicine. 367 (6): 520–531. doi:10.1056/NEJMoa1200920. ISSN 1533-4406. PMID 22873532. Unknown parameter
|coauthors=ignored (help)